Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Hoffmann-La Roche Inc.

Roche Diagnostics Operations, Inc.

F. Hoffmann-La Roche Ag

Helmut Lenz

Winfried Albert

Hans-Georg Batz

Joachim Ziegenhorn

Johann Karl

Joachim Siedel

Ulrich Neumann

Christa Hubner-Parajsz

Brigitte Pautz

Werner Scheuer

Albert Roder

Herbert Jungfer

Hans-Ralf Linke

Beatus Ofenloch-Hahnle

Hans Hornauer

Hartmut Schetters

Norbert Franken

Klaus Erler

Ursula Klause

Brigitte Kaluza

Werner Stock

Max Hasmann

Hans-Peter Josel

Christoph Seidel

Kay-Gunnar Stubenrauch

Urban Schmitt

Elke Faatz

Wolfgang Gruber

Rainer Rudolph

Rainer Mueller

Ralf Mattes

Peter Sluka

Werner Hoelke

Ulrich Weidle

August W Wahlefeld

Fritz Stahler

Volker Klemt

Christine Markert-Hahn

Manfred Baier

Dittmar Schlieper

Nicholas R Hoyle

Gerd Kleinhammer

Kurt W Naujoks

Karl Wulff

Martin Kaufmann

Friedemann Krause

Rainer Wehner

Martin Gerber

Anja-Katrin Bosserhoff

Siegfried Looser

Bernhard Eckert

Wolfgang Mutter

Helmut Rehner

Wolfgang Hoesel

Wolfgang Hosel

Ellen Moessner

Peter Bialk

Paul Tanswell

Hans-George Batz

Reinhard Buttner

Peter Stegmuller

Harald Haug

Ellen Mossner

Jochen Peter

Albert Kunst

Iise Bartke

Sabine Nussbaum

Beata Kanne

Gerald Praast

Willie Gerhardt

Johann Berger

Peter Finckh

Robert C McCarthy

Johannes Buchner

This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label

The invention concerns a method for determining antigen-specific antibodies of a particular immunoglobulin class in a sample by means of an immunoassay in an array format in which various binding partners Bare bound on different discrete areas on a support where Bin each case contain the various antigens that are able to specifically bind to the antibodies to be detected, by incubating the support with the sample and a binding partner Bwhich carries a label and subsequently detecting the label on the respective discrete areas wherein Bspecifically binds antibodies of a certain immunoglobulin class that have been bound in an antigen-specific manner.

Immune complex-specific antibodies for increased sensitivity in immunoassay array tests

The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody. A monoclonal antibody directed to a certain epitope that is present on all classes of human immunoglobulin of class G, but not on the immunoglobulin of any experimental animal except on the IgG of chimpanzees was used (MAB-M-R10Z8E9).

Detection of a therapeutic antibody in an experimental animal

By deglycosylating an enzyme derived from a eukaryotic organism prior to forming a conjugate, i.e. prior to attaching the enzyme to a molecule capable of binding to a target molecule, the sensitivity of an assay for detecting the presence or determining the quantity of a target molecule, in which the conjugate is used as a labelled component, can be increased. The present invention provides conjugates, methods for providing the same, use of such conjugates as well as kits containing the conjugates.

Deglycosylated enzymes for conjugates

The use of polyalkylene oxide modified reagents is disclosed in a method for the detection of an analyte or in suitable reagent kits for such methods.

Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods

A solid phase with at least one test area is described which contains reagents for the detection of at least one analyte in a sample, wherein the solid phase additionally comprises at least one control area for the detection of interfering reactions.

Use of check surfaces for identifying disturbing samples in a detection procedure

The invention concerns a method for the purification of a target substance from a biological sample by immobilizing the target substance on a solid phase by means of a high affinity binding pair and subsequently eluting it by adding a partner of the binding pair in a free form. In addition reagent kits for carrying out the method are disclosed.

Purification of substances from a biological sample

The invention concerns an immunological process for the detection of an analyte in a sample, in particular of tumor markers wherein for the reduction of interference substances containing a peptide sequence derived from the framework regions of the variable domain of the antibodies to be detected or the antibodies used for immune therapy or scintigraphy are added to the test preparation. Furthermore, the invention concerns the use of such substances for the reduction of interference of immunoassays, a suppressive agent and a process for the reduction of interference of immunoassays by the substances mentioned.

Reduction of interference of immunoassays by substances derived from the framework regions of antibodies

In order to extend the measuring range and to reduce the Hook effect in an immunological method of determination of an antigen based on the principle of a sandwich assay it is preferable to use a method which is characterized in that the labelled detection molecule is an oligomer of a binding molecule selected from antibody or/and antibody fragment.

Method for reducing hook effect in an immunoassay

The invention concerns the use of peptides which are comprised essentially of D-amino acids to eliminate interference in diagnostic methods, a method for eliminating interference in diagnostic methods by peptides which are comprised essentially of D-amino acids as well as a reagent that eliminates interference containing at least one peptide which is comprised essentially of D-amino acids.

Elimination of interference in diagnostic methods by peptides comprising

For the production of hetero-bispecific monoclonal antibodies at least the genes for the light chain and for the variable part of the heavy chain are isolated from a hybridoma cell line which secretes an antibody with a desired specificity and they are inserted into a eukaryotic plasmid vector which contains a marker capable of selection together with a strong promoter, this expression vector is transfected into a hybridoma cell line which secretes antibodies with a second desired specificity, the cell line is cultured, the antibodies are obtained and the bispecific antibody is isolated.

Process for the production of hetero-bispecific antibodies

The subject matter of the present invention are high-affinity monoclonal antibodies against MIA (Melanoma inhibitory activity) in native conformation, which can be used for the detection of malignant melanomas, their use for the detection of MIA as well as immunoassays for the detection of MIA.

Immunoassay for the detection of MIA

Antibody class-specific interference eliminating reagent

The present invention concerns a method for the determination of an analyte in a sample liquid using a metal complex capable of luminescence as an analyte-specific marker group for the production of a measuring signal in which an unspecific metal complex is additionally added as an interference elimination reagent which has a structure that is chemically related to the marker group.

Interference elimination reagent for the determination of an analyte

Growing community of inventors

Tutzing, Germany

Helmut Lenz